Biotech Values

[poorgradstudent]

SGYP:

I'm wondering why you said Linzess might have a slight edge in efficacy? Did you compare Phase 3 trial results?

I'm being generous for the sake of the comparison. The SGYP trial had 21% responders in 3 mg versus 10% on placebo. You could look at that as a +11%. In one of the Linzess trials, 21% responded to drug versus 3% on placebo, or +18%. The other Linzess trial showed a +10% (16%-6%).

In this regard, people can look at the numbers and say it is an efficacy versus side effect trade-off. That's why I don't think SGYP is necessarily gobble up all the scripts within a few months.